Seres Names Kurt Graves To Board
This article was originally published in Scrip
Seres Therapeutics, a microbiome therapeutics platform company, has appointed Kurt Graves to its board of directors. Graves, the chair, president and CEO of Intarcia Therapeutics, brings to Seres extensive experience from his 25-year career at top-tier pharmaceutical and biotech companies. He has held the position of chair, president and CEO of Intarcia since April 2012, having previously served as the company's executive chair since 2010 and acting CEO since October 2011. Before joining Intarcia, Graves was executive vice president, chief commercial officer and head of corporate and strategic development at Vertex Pharmaceuticals. Graves is already chair of the board of Radius Health, and a director on the boards of both Achillion Pharmaceuticals and Pulmatrix Pharmaceuticals.
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.